Cargando…
Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients
It is now reported that coronavirus disease 2019 ICU patients are at increased risk of thrombosis. Expert opinion and scientific societies recommend a higher dose of low-molecular-weight heparin, but definitive data is lacking. We report our adapted thromboprophylaxis practice of low-molecular-weigh...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392617/ https://www.ncbi.nlm.nih.gov/pubmed/32766568 http://dx.doi.org/10.1097/CCE.0000000000000177 |
_version_ | 1783564881483530240 |
---|---|
author | Piagnerelli, Michaël Cauchie, Philippe Vancutsem, Maxime Thooft, Aurélie Zouaoui Boudjeltia, Karim Biston, Patrick Wautrecht, Jean-Claude |
author_facet | Piagnerelli, Michaël Cauchie, Philippe Vancutsem, Maxime Thooft, Aurélie Zouaoui Boudjeltia, Karim Biston, Patrick Wautrecht, Jean-Claude |
author_sort | Piagnerelli, Michaël |
collection | PubMed |
description | It is now reported that coronavirus disease 2019 ICU patients are at increased risk of thrombosis. Expert opinion and scientific societies recommend a higher dose of low-molecular-weight heparin, but definitive data is lacking. We report our adapted thromboprophylaxis practice of low-molecular-weight heparin administration in coronavirus disease 2019 ICU patients. One-hundred six measurements in 19 ICU patients were collected. Despite enoxaparin 60 mg once daily, only two measurements of the trough anti-Xa were in the upper end of prophylactic range. Anti-Xa activity peaks increased significantly after administration, but all measurements were under the optimal prophylactic ranges. Despite an adapted protocol, three of the 19 patients (16%) developed venous thromboembolism. We show in coronavirus disease 2019 ICU patients, despite higher prophylactic low-molecular-weight heparin administration due to body mass index, anti-Xa activity was well below peak serum levels in our cohort of critically ill coronavirus disease 2019 patients. This evaluation suggests the need for rapid studies on adequate thromboprophylaxis in these patients. |
format | Online Article Text |
id | pubmed-7392617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-73926172020-08-05 Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients Piagnerelli, Michaël Cauchie, Philippe Vancutsem, Maxime Thooft, Aurélie Zouaoui Boudjeltia, Karim Biston, Patrick Wautrecht, Jean-Claude Crit Care Explor Letter to the Editor It is now reported that coronavirus disease 2019 ICU patients are at increased risk of thrombosis. Expert opinion and scientific societies recommend a higher dose of low-molecular-weight heparin, but definitive data is lacking. We report our adapted thromboprophylaxis practice of low-molecular-weight heparin administration in coronavirus disease 2019 ICU patients. One-hundred six measurements in 19 ICU patients were collected. Despite enoxaparin 60 mg once daily, only two measurements of the trough anti-Xa were in the upper end of prophylactic range. Anti-Xa activity peaks increased significantly after administration, but all measurements were under the optimal prophylactic ranges. Despite an adapted protocol, three of the 19 patients (16%) developed venous thromboembolism. We show in coronavirus disease 2019 ICU patients, despite higher prophylactic low-molecular-weight heparin administration due to body mass index, anti-Xa activity was well below peak serum levels in our cohort of critically ill coronavirus disease 2019 patients. This evaluation suggests the need for rapid studies on adequate thromboprophylaxis in these patients. Lippincott Williams & Wilkins 2020-07-29 /pmc/articles/PMC7392617/ /pubmed/32766568 http://dx.doi.org/10.1097/CCE.0000000000000177 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Letter to the Editor Piagnerelli, Michaël Cauchie, Philippe Vancutsem, Maxime Thooft, Aurélie Zouaoui Boudjeltia, Karim Biston, Patrick Wautrecht, Jean-Claude Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients |
title | Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients |
title_full | Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients |
title_fullStr | Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients |
title_full_unstemmed | Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients |
title_short | Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients |
title_sort | thromboprophylaxis in critically ill coronavirus disease 2019 patients |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392617/ https://www.ncbi.nlm.nih.gov/pubmed/32766568 http://dx.doi.org/10.1097/CCE.0000000000000177 |
work_keys_str_mv | AT piagnerellimichael thromboprophylaxisincriticallyillcoronavirusdisease2019patients AT cauchiephilippe thromboprophylaxisincriticallyillcoronavirusdisease2019patients AT vancutsemmaxime thromboprophylaxisincriticallyillcoronavirusdisease2019patients AT thooftaurelie thromboprophylaxisincriticallyillcoronavirusdisease2019patients AT zouaouiboudjeltiakarim thromboprophylaxisincriticallyillcoronavirusdisease2019patients AT bistonpatrick thromboprophylaxisincriticallyillcoronavirusdisease2019patients AT wautrechtjeanclaude thromboprophylaxisincriticallyillcoronavirusdisease2019patients |